| Literature DB >> 24386593 |
Christian Obirikorang1, Peter Kuugemah Selleh2, Jubilant Kwame Abledu3, Chris Opoku Fofie4.
Abstract
Background. The effectiveness of ART interventions is only realized in maximal levels of adherence. A near perfect adherence level of >95% is required for the effective suppression of HIV/AIDS virus. The main objective of this study was to identify the sociodemographic and socioeconomic factors that facilitate adherence to antiretroviral therapy among HIV/AIDS patients. Methods. This descriptive cross-sectional study was conducted between March and May 2013 at the Upper West Regional Hospital, Wa. A total of 201 confirmed HIV 1 seropositive subjects (mean age 36.6 ± 9.9 years) receiving antiretroviral therapy were interviewed using a structured questionnaire. The collected data was analyzed using GraphPad Prism version 5. A P value of <0.05 was considered statistically significant for all statistical analyses. Results. Overall lifetime adherence was found to be 62.2% while medication adherence in the last six months, last three months, last month, and last week were 73.6%, 87.1%, 91.0%, and 86.0%, respectively. The study revealed a positive association between adherence to ART and immunological success, with nonadherence increasing the risk (OR (95% CI): 9.2 (3.2-26.9)) of immunological failure. Univariate logistic regression analysis of the data showed that other ailments and side effects of drug were negatively associated with adherence to ART whereas self-perceived wellness, family support, and regular followup were positively associated with adherence to ART. Conclusion. Regular attendance at followup and family support are vital factors for 100% lifetime medication adherence. Effective counseling sessions on adherence for patients on antiretroviral therapy are paramount for the realization of the purpose of antiretroviral therapy programmes in Ghana.Entities:
Year: 2013 PMID: 24386593 PMCID: PMC3872409 DOI: 10.1155/2013/873939
Source DB: PubMed Journal: ISRN AIDS ISSN: 2090-939X
Patient demographics relative to medication adherence.
| Parameter | Total (%) | No (%) | Yes (%) |
|
|---|---|---|---|---|
| Missed medications in lifetime | ||||
| Ever missed medications since starting ART | 201 (100) | 125 (62.2) | 76 (37.8) | |
| Missed medications in the last 6 months | 201 (100) | 148 (73.6) | 53 (26.4) | |
| Missed medications in the last 3 months | 201 (100) | 175 (87.1) | 26 (12.9) | |
| Missed medications in the last month | 201 (100) | 183 (91.0) | 18 (9.0) | |
| Missed medications in the last week | 201 (100) | 172 (86.0) | 28 (14.0) | |
| Age | ||||
| 20–30 | 64 (32.5) | 38 (59.4) | 26 (40.6) | |
| 31–40 | 83 (42.1) | 53 (63.9) | 30 (36.1) | 0.3401 |
| >40 | 50 (25.4) | 34 (68.0) | 16 (32.0) | |
| Sex | ||||
| Male | 42 (20.9) | 24 (57.1) | 18 (42.9) | 0.4774 |
| Female | 159 (79.1) | 101 (63.5) | 58 (36.5) | |
| Marital status | ||||
| Married | 105 (52.2) | 62 (59.0) | 43 (41.0) | |
| Widowed | 45 (22.4) | 28 (62.2) | 17 (37.8) | 0.7060 |
| Divorced | 30 (14.9) | 21 (70.0) | 9 (30.0) | |
| Single | 21 (10.4) | 14 (66.7) | 7 (33.3) | |
| Education | ||||
| No education | 102 (50.7) | 62 (60.8) | 40 (39.2) | |
| Primary | 31 (15.4) | 21 (67.4) | 10 (32.3) | |
| JHS/middle school | 49 (24.4) | 30 (61.2) | 19 (38.8) | 0.7223 |
| SHS | 10 (5.0) | 5 (50.0) | 5 (50.0) | |
| Tertiary | 9 (4.5) | 7 (77.8) | 2 (22.2) | |
| Family type | ||||
| Nuclear | 106 (52.7) | 59 (55.7) | 47 (44.3) | |
| Extended | 67 (33.3) | 46 (68.7) | 21 (31.3) | 0.1268 |
| Living alone | 28 (13.9) | 20 (71.4) | 8 (28.6) | |
| Monthly income | ||||
| ≤100 | 104 (92.0) | 71 (68.3) | 33 (31.7) | |
| 101–500 | 7 (6.2) | 5 (71.4) | 2 (28.6) | 0.6238 |
| >500 | 2 (1.8) | 2 (100.0) | 0 (0.0) | |
| Time since ART (years) | ||||
| <1 | 7 (3.5) | 1 (14.3) | 6 (85.7) | |
| 1–4 | 163 (81.1) | 66 (40.5) | 97 (58.4) | 0.2058 |
| 5+ | 31 (15.4) | 9 (29.0) | 22 (71.0) | |
| Time since diagnosis (years) | ||||
| <1 | 3 (1.5) | 0 (0.0) | 3 (100.0) | |
| 1–4 | 158 (78.6) | 62 (39.2) | 96 (60.8) | 0.3507 |
| 5+ | 40 (19.9) | 14 (35.0) | 26 (65.0) | |
| Immunological success | ||||
| Yes | 96 (78.7) | 66 (68.8) | 30 (31.3) |
|
| No* | 26 (21.3) | 5 (19.2) | 21 (80.8) |
Data are presented as proportions. Proportions are compared using Fisher's exact test and the chi-square test where applicable. *(OR: 9.2; 95% CI: 3.2–26.9).
Patient antiretroviral therapy and disease characteristics.
| Parameter | Frequency/percentage |
|---|---|
| CD4 at diagnosis (cells/mm3) | |
| <100 | 26 (15.1) |
| 101–200 | 35 (20.3) |
| 201–300 | 56 (32.6) |
| >300 | 55 (32.0) |
| Current ART regimen | |
| Nevirapine based | 84 (41.8) |
| Efavirenz based | 66 (32.8) |
| Nevirapine based + septrin | 30 (14.9) |
| Efavirenz based + septrin | 17 (8.5) |
| Septrin | 4 (2.0) |
| Current CD4 (cells/mm3) | |
| <100 | 1 (0.6) |
| 101–200 | 4 (2.4) |
| 201–300 | 21 (12.5) |
| >300 | 142 (84.5) |
| Reason for missing ART | |
| Forgetfulness | 35 (46.1) |
| No food to take with | 7 (9.2) |
| Away from home | 12 (15.8) |
| Felt sick | 2 (2.6) |
| Busy | 3 (3.9) |
| Run out of drugs | 32 (42.1) |
Data are presented as frequency and percentage. Data may not add up to 201 due to missing data.
Logistic regression of patient characteristics associated with medication adherence.
| Characteristic | Total | Nonadherent | Adherent | OR (95% CI) |
| aOR (95% CI) |
|
|---|---|---|---|---|---|---|---|
| Food restriction | |||||||
| Yes | 183 (91.5) | 71 (38.8) | 112 (61.2) | 0.7 (0.2–1.9) | 0.3896 | ||
| Other ailments | |||||||
| Yes | 29 (14.4) | 20 (69.0) | 9 (31.0) | 0.2 (0.1–0.5) |
| 0.3 (0.1–0.8) |
|
| No* | 167 (85.2) | 54 (32.3) | 113 (67.7) | 1 | 1 | ||
| Side effects | |||||||
| Yes | 35 (17.4) | 26 (74.2) | 9 (25.7) | 0.2 (0.1–0.4) |
| 0.2 (0.1–0.6) |
|
| No* | 166 (82.6) | 50 (30.1) | 116 (69.9) | 1 | 1 | ||
| Perceived difficulty of drug regimen | |||||||
| Simple* | 94 (46.8) | 41 (43.6) | 53 (56.4) | 1 | |||
| Moderate | 100 (49.8) | 31 (31.0) | 69 (69.0) | 1.7 (1.0–3.1) | 0.0701 | ||
| Difficult | 7 (3.4) | 4 (57.1) | 3 (42.9) | 0.6 (0.1–2.7) | 0.4916 | ||
| Perceived well-being | |||||||
| Normal* | 143 (71.5) | 69 (48.3) | 74 (51.7) | 1 | 1 | ||
| Very healthy | 54 (27.0) | 5 (9.3) | 49 (90.7) | 9.0 (3.4–23.9) |
| 4.2 (1.5–12.1) |
|
| Sick | 3 (1.5) | 2 (66.7) | 1 (33.3) | 0.5 (0.1–5.2) | 0.5299 | ||
| Disclosure | |||||||
| Yes | 158 (79.0) | 63 (39.9) | 95 (60.1) | 1.5 (0.7–3.1) | 0.2915 | ||
| No* | 42 (21.0) | 13 (31.0) | 29 (69.0) | 1 | |||
| Family support | |||||||
| Yes | 139 (69.2) | 46 (33.1) | 93 (66.9) | 1.9 (1.1–3.5) |
| 0.9 (0.4–2.0) |
|
| No* | 62 (30.8) | 30 (48.4) | 32 (51.6) | 1 | 1 | ||
| Followup | |||||||
| Regular | 158 (78.6) | 42 (26.6) | 116 (73.4) | 10.4 (4.6–23.6) |
| 6.9 (2.8–17.0) |
|
| Irregular* | 43 (21.4) | 34 (79.1) | 9 (20.9) | 1 | 1 |
*Reference. Data are presented as proportions. Regular followup implies more than 90% attendance at 3 monthly appointments. OR: odds ratio, aOR: adjusted odds ratio, CI: confidence interval. Data may not add up to 201 due to missing data. Other ailments (0: no; 1: yes); perception of well-being (1: normal; 2: very healthy; 3: sick); side effects (0: no; 1: yes); support from family (0: no; 1: yes); followup (0: irregular; 1: regular-0) Perceived difficulty of drug regimen (simple: 1; moderate: 2; difficult: 3) Disclosure (yes: 1; no: 0).
Figure 1Adherence levels based on patient's antiretroviral therapy combinations.